SCHEMBL1111572

SCHEMBL1111572

CCC1(C(CC=CI)O[Si](C)(C)C(C)(C)C)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1111568 1.00
SCHEMBL7956129 0.89
SCHEMBL5168798 0.89
SCHEMBL3366060 0.89
SCHEMBL3366057 0.89
SCHEMBL7207357 0.86
SCHEMBL4025513 0.77 HSD11B1 (0.31)
SCHEMBL4025524 0.77 HSD11B1 (0.31)
SCHEMBL2000021 0.76
SCHEMBL1327659 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193373-B2 Therapeutic compounds ALLERGAN, INC. (US) 2012-06-05 US disclosed
US-7960378-B2 Therapeutic compounds ALLERGAN, INC. (US) 2011-06-14 US disclosed
EP-2279169-A2 THERAPEUTIC COMPOUNDS Allergan, Inc. (US) 2011-02-02 EP disclosed
US-20100063303-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2010-03-11 US disclosed
US-20090239930-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2009-09-24 US disclosed
WO-2009117467-A2 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2009-09-24 WO disclosed
EP-1042283-B1 OMEGA-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES ONO PHARMACEUTICAL CO (JP) 2004-02-25 EP disclosed
US-6262293-B1 CLATHRATE COMPOUNDS ONO PHARMACEUTICAL CO., LTD. (JP) 2001-07-17 US disclosed
EP-1042283-A1 $g(v)-CYCLOALKYL-PROSTAGLANDIN E 2? DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 2000-10-11 EP disclosed
WO-1999033794-A1 φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 1999-07-08 WO disclosed